Signature Proteins in Small Extracellular Vesicles of Granulocytes and CD4+ T-Cell Subpopulations Identified by Comparative Proteomic Analysis
Authors:
- Sara Vázquez-MeraSVSara Vázquez-Mera
- Pablo Miguéns-SuárezPMPablo Miguéns-Suárez
- Laura Martelo-VidalLMLaura Martelo-Vidal
- Sara Rivas-LópezSRSara Rivas-López
- Lena UllerLULena Uller
- Susana B. BravoSBSusana B. Bravo
- Vicente Domínguez-ArcaVDVicente Domínguez-Arca
- Xavier MuñozXMXavier Muñoz
- Francisco J. González-BarcalaFGFrancisco J. González-Barcala
- Juan J. Nieto FontarigoJFJuan J. Nieto Fontarigo
- Francisco J. SalgadoFSFrancisco J. Salgado
Open Access
- 9 October 2024
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (19) , 10848
Abstract
Several studies have described the proteomic profile of different immune cell types, but only a few have also analysed the content of their delivered small extracellular vesicles (sEVs). The aim of the present study was to compare the protein signature of sEVs delivered from granulocytes (i.e., neutrophils and eosinophils) and CD4+ T cells (i.e., TH1, TH2, and TH17) to identify potential biomarkers of the inflammatory profile in chronic inflammatory diseases. Qualitative (DDA) and quantitative (DIA-SWATH) analyses of in vitro-produced sEVs revealed proteome variations depending on the cell source. The main differences were found between granulocyte- and TH cell-derived sEVs, with a higher abundance of antimicrobial proteins (e.g., LCN2, LTF, MPO) in granulocyte-derived sEVs and an enrichment of ribosomal proteins (RPL and RPS proteins) in TH-derived sEVs. Additionally, we found differentially abundant proteins between neutrophil and eosinophil sEVs (e.g., ILF2, LTF, LCN2) and between sEVs from different TH subsets (e.g., ISG15, ITGA4, ITGB2, or NAMPT). A “proof-of-concept” assay was also performed, with TH2 biomarkers ITGA4 and ITGB2 displaying a differential abundance in sEVs from T2high and T2low asthma patients. Thus, our findings highlight the potential use of these sEVs as a source of biomarkers for diseases where the different immune cell subsets studied participate, particularly chronic inflammatory pathologies such as asthma or chronic obstructive pulmonary disease (COPD).Keywords
Funding Information
- Instituto de Salud Carlos III (PI17/01655, RYC2021-032676-I)
- MCIN/AEI/10.13039/501100011033 (PI17/01655, RYC2021-032676-I)
- European Social Fund, ESF (PI17/01655, RYC2021-032676-I)
This publication has 80 references indexed in Scilit:
- Exosomes as biomarkers and therapeutic delivery for autoimmune diseases: Opportunities and challengesAutoimmunity Reviews, 2022
- Lipocalin-2: Structure, function, distribution and role in metabolic disordersBiomedicine & Pharmacotherapy, 2021
- SWATH-MS Protocols in Human Diseases2021
- Neutralization of extracellular NAMPT (nicotinamide phosphoribosyltransferase) ameliorates experimental murine colitisJournal of Molecular Medicine, 2020
- Proteomic analysis of human T cell‐derived exosomes reveals differential RAS/MAPK signalingEuropean Journal of Immunology, 2018
- Understanding Asthma Phenotypes, Endotypes, and Mechanisms of DiseaseClinical Reviews in Allergy & Immunology, 2018
- Exosomes contribute to the transmission of anti-HIV activity from TLR3-activated brain microvascular endothelial cells to macrophagesAntiviral Research, 2016
- The circulating microRNome demonstrates distinct lymphocyte subset‐dependent signaturesEuropean Journal of Immunology, 2015
- Immune Response to Seasonal Influenza A Virus Infection: A Proteomic ApproachArchives of Medical Research, 2012
- Isolation and Characterization of Exosomes from Cell Culture Supernatants and Biological FluidsCurrent Protocols in Cell Biology, 2006